On Feb 25, 2015, The Food and Drug Administration (FDA) announced the availability of a draft guidance entitled “Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices”. This draft guidance provides industry and Agency staff with recommendations regarding the technical performance assessment data that should be submitted for regulatory evaluation of a digital whole slide imaging (WSI) system. This draft guidance is not final nor is it in effect at this time.
Unless otherwise stated, all texts, graphics, user interface, visual interface, images, and computer codes (referred to collectively as the Contents) on the Website, including but not limited to the design, structure, selection, coordination, expression, look of interface or images and sorting of these Contents, are all owned by the Digital Pathology Association or its licensor. We are not responsible for the display of the cell images, as they are rendered on different browsers and platforms. Images on this site should not be used in the assessment or diagnosing process. Please contact the DPA, for more information.